HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 11-08-2006, 06:11 PM   #1
tousled1
Senior Member
 
tousled1's Avatar
 
Join Date: Feb 2006
Location: Acworth, GA
Posts: 2,104
Breast Cancer Responds to Shorter-Course Radiation

Study suggests treatment can be reduced by three weeks
WEDNESDAY, Nov. 8 (HealthDay News) -- A shorter course of external beam radiation therapy for early-stage breast cancer is both safe and effective, new U.S. research shows.

Many women with early breast cancer have breast-sparing surgery (lumpectomy) followed by treatment with external beam radiation five days a week for six to seven weeks.

This study of 75 patients concluded that the intensity modulated radiation treatment (IMRT) can be safely done in four weeks by increasing the daily dose of radiation.

The findings were expected to be presented Wednesday at the annual meeting of the American Society for Therapeutic Radiology and Oncology, in Philadelphia.

"We know the standard regimen of daily radiation five days a week for six to seven weeks is a tremendous time commitment for women who are often still working or providing family care or both," study lead author Dr. Gary Freedman, a radiation oncologist at Fox Chase Cancer Center in Philadelphia, said in a prepared statement.

"Our goal in this research was to reduce the burden of treatment time while maintaining a high level of quality of life issues," Freedman said.

He and his colleagues measured toxicity, pain and cosmetic outcomes for the women who received the shorter course of IMRT and compared those results to data on women who had the usual course of therapy.

The researchers found little or no difference between the two groups.

"These results demonstrate that the increased daily radiation given to the breast does not result in significant increased side effects, but it allows us to dramatically reduce the time needed for treatment," Freedman said.

"Longer follow-up is needed to compare the outcomes at five years after treatment," he added.
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
tousled1 is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 11:32 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter